NCT02486601View on ClinicalTrials.gov

NAB-PACLITAXEL Plus FOLFOX as Perioperative Chemotherapy in Patients With Operable Oesogastric Adenocarcinoma

PHASE2UnknownINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

October 31, 2017

Study Completion Date

June 30, 2022

Conditions
Cancer of Stomach
Interventions
DRUG

nab-paclitaxel

nab-paclitaxel : 150 mg/m2 D1 every 2 weeks

DRUG

FOLFOX

Leucovorin: 400 mg/m2 D1 every 2 weeks Oxaliplatin: 85 mg/m2 D1 every 2 weeks Fluorouracil (5-FU) infusion: 2400mg/m2 48h infusion every 2 weeks

Trial Locations (7)

25030

RECRUITING

Centre Hospitalier Regional de Besancon - Hopital Jean Minjoz, Besançon

75651

RECRUITING

CHU Pitie-Salpetriere, Paris

94000

RECRUITING

Centre Hospitalier Universitaire Henri Mondor, Créteil

Unknown

RECRUITING

Centre Léon Bérard, Lyon

RECRUITING

Hôpital Privé Jean Mermoz, Lyon

RECRUITING

Hopital Saint Antoine, Paris

RECRUITING

Institut Mutualiste Montsouris, Paris

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

GERCOR - Multidisciplinary Oncology Cooperative Group

OTHER

NCT02486601 - NAB-PACLITAXEL Plus FOLFOX as Perioperative Chemotherapy in Patients With Operable Oesogastric Adenocarcinoma | Biotech Hunter | Biotech Hunter